TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17635283
Drug: Bolus group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus group (pantoprazole 80 mg i.v. bolus followed by 40 mg i.v. bolus every 12 h for 3 days)
Study: 17635283
Drug: No-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment group (no acid suppression in the first 3 days)
Study: 17635283
Drug: Infusion group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion group vs Bolus group
Study: 7791015
Drug: Intracervical 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical 0.5 mg PGE2 gel
Study: 7791015
Drug: Intravaginal 3
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal 3 mg PGE2 tablet
Study: 30916733
Drug: Drug-deactivation bag
Normalized name: obecabtagene autoleucel
DrugBank: Obecabtagene autoleucel (DB17362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-deactivation bag
Study: 29176768
Drug: Open administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open administration of expressive writing intervention
Study: 29176768
Drug: Hidden administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hidden administration of expressive writing intervention
Study: 23514584
Drug: Temsirolimus monotherapy
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus monotherapy (25 mg weekly)
Study: 23514584
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (irinotecan 180 mg/m2 biweekly + temsirolimus)
Study: 8915019
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment on a non-adjacent tooth with persistent or recurrent periodontitis
Study: 1856141
Drug: Amikacin 15
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin 15 mg/kg/day given as a single dose
Study: 1856141
Drug: Amikacin 15
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin 15 mg/kg/day given in two divided doses at 12‐h intervals
Study: 6349646
Drug: Meclofenamate sodium,
Normalized name: Meclofenamate Sodium, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclofenamate sodium, 200 mg/day
Study: 6349646
Drug: Meclofenamate sodium,
Normalized name: Meclofenamate Sodium, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclofenamate sodium, 300 mg/day
Study: 6349646
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA), 3.6 g/day
Study: 29947474
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg orally disintegrating film
Study: 29947474
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg film-coated tablets (Viagra®, Pfizer, Mexico)
Study: 28438118
Drug: Rifampicin-based regimens
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin-based regimens (R10, 15 and 20 mg/Kg)
Study: 19247202
Drug: CIFN induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIFN induction therapy (27 or 18 mg q.d.)
Study: 11577792
Drug: Postoperative chemoradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative chemoradiation therapy
Study: 11577792
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy or chemoradiation
Study: 11577792
Drug: Various chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various chemotherapy regimens
Study: 9205931
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (nitrendipine 10-40 mg/day, possibly with enalapril 5-20 mg/day and/or hydrochlorothiazide 12.5-25 mg/day)
Study: 8035470
Drug: Therapeutic self-disclosure
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic self-disclosure in couples during 10 weekly sessions
Study: 29957868
Drug: Camicinal 50
Normalized name: Camicinal
DrugBank: Camicinal (DB12567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camicinal 50 mg daily for a maximum of 7 days
Study: 23721984
Drug: Combination program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination program (yoga therapy and lifestyle modification)
Study: 18362654
Drug: Topical mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical mitomycin C (MMC) 0.2 mg/mL
Study: 12760984
Drug: Acetaminophen 10
Normalized name: acetaminophen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 10 mg/kg orally (Control)
Study: 12760984
Drug: Acetaminophen 10
Normalized name: acetaminophen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 10 mg/kg with 1 mg/kg of codeine orally
Study: 12760984
Drug: Transnasal butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transnasal butorphanol 25 micro g/kg given immediately after the induction of anesthesia
Study: 12760984
Drug: Ketorolac 1
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 1 mg/kg given IM immediately after the induction of anesthesia
Study: 1425888
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine system (TNS) 30 cm2
Study: 6377487
Drug: Exposure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure treatment until day 14 post-burn, followed by excision and grafting of non-spontaneously healed areas (group E, 76 patients)
Study: 24852569
Drug: Oral UDCA
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral UDCA treatment (ursodeoxycholic acid) after esophageal perfusion with DCA (250 μM) for 8 weeks
Study: 22058145
Drug: UDCA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA treatment
Study: 15807285
Drug: Repaglinide (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (1.0 mg tid)
Study: 15807285
Drug: Nateglinide (90.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (90.0 mg tid)
Study: 12040357
Drug: 1800 mg
Normalized name: glycerin 1800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg of WS 1442
Study: 12040357
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of WS 1442
Study: 17007849
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg anastrozole
Study: 15998903
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tamoxifen and anastrozole
Study: 497090
Drug: Pivampicillin tablets
Normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin tablets
Study: 497090
Drug: Pivampicillin capsules
Normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin capsules
Study: 497090
Drug: Pivampicillin capsules
Normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin capsules and tablets
Study: 29668860
Drug: Chemotherapy (pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (pemetrexed 500 mg/m2 or docetaxel 75 mg/m2, both every 3 weeks)
Study: 18405147
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and medication
Study: 18405147
Drug: Medication (Methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Methyl vitamin B12 250 microg, once daily)
Study: 2686956
Drug: Beclobrate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclobrate (100 mg)
Study: 8735678
Drug: Bezafibrate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (400 mg)
Study: 7884019
Drug: Amitriptyline 150
Normalized name: amitriptyline 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 150 mg per day
Study: 31907004
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C) continuing with standardized treatment schedule of MTX 15 mg/week
Study: 30418115
Drug: Oral steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroid or nbDMARD use
Study: 30418115
Drug: Reason for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reason for not modifying therapy
Study: 25403846
Drug: Ibandronate treatment
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate treatment for 3 years
Study: 19459079
Drug: Superoxidized solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superoxidized solution (SOS)
Study: 17299118
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and exercise intervention (3-month duration, daily energy deficit of -45.7 +/- 12.4%)
Study: 9808499
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (GCV) 1000 mg every 8 hr for CrCl >50 ml/min
Study: 9808499
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (GCV) 1000 mg every 24 hr for CrCl of 25-50 ml/min
Study: 9808499
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (GCV) 500 mg every day for CrCl of 10-24 ml/min
Study: 9808499
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (GCV) 500 mg every other day after dialysis for CrCl <10 ml/min
Study: 9808499
Drug: Absolute bioavailability
Normalized name: Honey Absolute
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absolute bioavailability of oral GCV
Study: 8694983
Drug: Oscillating/rotating electric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oscillating/rotating electric toothbrush (Braun Oral‐B Plaque Remover)
Study: 189655
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with vincristine and actinomycin D for 6 months
Study: 189655
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with vincristine and actinomycin D for 15 months
Study: 30147355
Drug: Oral methylnaltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methylnaltrexone 300 mg/day
Study: 30147355
Drug: Oral methylnaltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methylnaltrexone 450 mg/day
Study: 25772444
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 30 (control)
Study: 21211644
Drug: Peptide vaccine
Normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide vaccine (3 nmol)
Study: 19411814
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of soy protein containing 160 mg of total isoflavones
Study: 19411814
Drug: Taste-matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taste-matched placebo (20 g whole milk protein)
Study: 25303140
Drug: Preventive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive chemotherapy
Study: 9920356
Drug: Alpha-tocopherol supplementation
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol supplementation (50 mg/day)
Study: 9920356
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (neither alpha-tocopherol nor ASA)
Study: 8048523
Drug: Rapid inflation
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid inflation (170 ml/s)
Study: 8048523
Drug: Slow inflation
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow inflation (0.7 ml/s)
Study: 29088019
Drug: CE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE 0.625 mg alone
Study: 29088019
Drug: CE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE 0.625 mg/BZA 5 mg
Study: 29088019
Drug: CE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE 0.625 mg/BZA 10 mg
Study: 29088019
Drug: CE 0.3
Normalized name: SODIUM HYALURONATE 0.24 g in 30 mL / PANAX GINSENG FLOWER 0.3 g in 30 mL / ZINC PCA 0.3 g in 30 mL / NIACINAMIDE 2.1 g in 30 mL / GREEN TEA LEAF 0.3 mg in 30 mL / LICORICE 0.3 mg in 30 mL / CHAMOMILE 0.45 mg in 30 mL TOPICAL LIQUID [Niacinamide Soothing Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE 0.3 mg/BZA 20 mg
Study: 29088019
Drug: CE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE 0.625 mg
Study: 29088019
Drug: CE 0.3
Normalized name: SODIUM HYALURONATE 0.24 g in 30 mL / PANAX GINSENG FLOWER 0.3 g in 30 mL / ZINC PCA 0.3 g in 30 mL / NIACINAMIDE 2.1 g in 30 mL / GREEN TEA LEAF 0.3 mg in 30 mL / LICORICE 0.3 mg in 30 mL / CHAMOMILE 0.45 mg in 30 mL TOPICAL LIQUID [Niacinamide Soothing Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE 0.3 mg with BZA 10 or 20 mg
Study: 26347109
Drug: Paclitaxel (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (200 mg/m²), carboplatin (AUC 6), bevacizumab (15 mg/kg) with nitroglycerin patches (15 mg, day -2 to +2)
Study: 26347109
Drug: Paclitaxel (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (200 mg/m²), carboplatin (AUC 6), bevacizumab (15 mg/kg) without nitroglycerin patches
Study: 16166782
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg prednisolone once daily in the evening
Study: 2016615
Drug: Levamisole 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole 2.5 mg/kg on 2 consecutive days weekly for 3 years
Study: 7259869
Drug: Korinfar 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korinfar 30 mg
Study: 7259869
Drug: Korinfar 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korinfar 50 mg
Study: 7259869
Drug: Isoptin 120
Normalized name: Isoptin 120 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoptin 120 mg
Study: 7259869
Drug: Isoptin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoptin 200 mg
Study: 7259869
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (Korinfar and Isoptin)
Study: 30597042
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitor (dapagliflozin: ≤10 mg/day)
Study: 23664436
Drug: Dabigatran 110
Normalized name: dabigatran 110 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 110 mg bid
Study: 23664436
Drug: Dabigatran 150
Normalized name: dabigatran 150 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 150 mg bid
Study: 20074388
Drug: Low-fat vegan
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat vegan diet with weekly group meetings
Study: 17038247
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition (EN) or EN supplemented with parenteral nutrition (EN+PN)
Study: 2635353
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment only (Control)
Study: 8878242
Drug: Azithromycin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (n = 341) once daily for 5 days
Study: 8878242
Drug: Amoxicillin/clavulanate (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (n = 336) three times daily for 10 days
Study: 8315799
Drug: Epidural buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural buprenorphine (Bn) 0.1-0.2 mg (group B, n = 41)
Study: 8315799
Drug: Epidural buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural buprenorphine (Bn) 0.1-0.2 mg + 1% lidocaine (group BL, n = 41)
Study: 8315799
Drug: Epidural buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural buprenorphine (Bn) 0.1-0.2 mg (group B)
Study: 8315799
Drug: Epidural buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural buprenorphine (Bn) 0.1-0.2 mg + 1% lidocaine (group BL)
Study: 3788741
Drug: Two 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 400 mg oral doses for a single day
Study: 3788741
Drug: Three 200
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 200 mg oral doses for three days
Study: 20664906
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg/day for days 1-10; 300 mg on day 11)
Study: 17971588
Drug: Cranial radiation
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial radiation therapy (CRT) with double intrathecal (IT) chemotherapy (methotrexate and cytarabine)
Study: 17971588
Drug: Intensive triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive triple IT chemotherapy (methotrexate, cytarabine and hydrocortisone) without CRT
Study: 12170410
Drug: 2-l PEG-EL
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-l PEG-EL solution
Study: 1829439
Drug: High-flux polysulfone
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flux polysulfone (PS) membrane with high heparin regimen (HHR) - 90 IU/kg body weight
Study: 1829439
Drug: High-flux polyacrylonitrile
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flux polyacrylonitrile (AN 69) membrane with high heparin regimen (HHR) - 90 IU/kg body weight
Study: 1829439
Drug: High-flux polysulfone
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flux polysulfone (PS) membrane with low heparin regimen (LHR) - 50 IU/kg body weight
Study: 1829439
Drug: High-flux polyacrylonitrile
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flux polyacrylonitrile (AN 69) membrane with low heparin regimen (LHR) - 50 IU/kg body weight
Study: 1829439
Drug: Low heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low heparin regimen (LHR)
Study: 30127374
Drug: Flaxseed consumption
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed consumption (30 g/day) for 12 weeks
Study: 24633366
Drug: EV71 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71 vaccine (batch 1)
Study: 24633366
Drug: EV71 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71 vaccine (batch 2)
Study: 24633366
Drug: EV71 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71 vaccine (batch 3)
Study: 31977278
Drug: EV71 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71 vaccine
Study: 16039195
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin treatment (short-acting insulin 1 IU.kg(‐1).h(‐1) with 30% glucose 1.5 mL.kg(‐1).h(‐1))
Study: 16039195
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin treatment
Study: 16923091
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (saline)
Study: 9808873
Drug: Recombinant tissue-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant tissue-type plasminogen activator (rt-PA) (100 mg)
Study: 9808873
Drug: Aspirin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (500 mg i.v. prior to thrombolytic therapy and 325 mg/day orally)
Study: 7655770
Drug: Oral sulpiride
Normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sulpiride (2 x 50 mg capsules, 200 mg tablets)
Study: 7655770
Drug: Intravenous sulpiride
Normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sulpiride (100 mg)
Study: 31065111
Drug: Eribulin (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin (1.4 mg/m² intravenously on day 1 and day 8)
Study: 31065111
Drug: Dacarbazine (850,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacarbazine (850, 1000, or 1200 mg/m² intravenously every 21 days)
Study: 29797389
Drug: Basal-bolus therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal-bolus therapy (BBT)
Study: 23095799
Drug: Carvedilol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (10 mg/day)
Study: 23095799
Drug: ARB (doubled
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB (doubled dose)
Study: 23095799
Drug: CCB (doubled
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCB (doubled dose)
Study: 19252451
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g SCE‐A cream (n = 150)
Study: 17681970
Drug: Ketamine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.15 mg kg(‐1) i.v. 5 min before induction of general anaesthesia
Study: 16402012
Drug: Johnson's Baby
Normalized name: Johnson's Baby
Approvals — FDA: no, EMA: no, PMDA: no
Description: Johnson's Baby products used daily for 8 weeks
Study: 16402012
Drug: Johnson's Baby
Normalized name: Johnson's Baby
Approvals — FDA: no, EMA: no, PMDA: no
Description: Johnson's Baby products used daily for 8 weeks in 186 newborns (92 female plus 94 male) aged 0-4 weeks
Study: 8599066
Drug: 2-1-1 schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-1-1 schedule (one dose in right arm and one in left arm at day 0, one dose on days 7 and 21)
Study: 8599066
Drug: Variant schedule
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variant schedule (double dose on day zero and another on day 14)
Study: 8599066
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses (2-1-1 schedule)